Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
Completed
POZEN
Phase 3
2007-09-01
This study uses a randomized, double-blind, controlled design to demonstrate that PN400
(esomeprazole and naproxen) is more effective in reducing the occurrence of gastroduodenal
ulcers, dyspepsia, and heartburn in subjects at risk for developing NSAID-associated gastric
ulcers compared to naproxen alone.
A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)
Completed
POZEN
Phase 3
2007-03-01
This study uses an open-label design and will be conducted in approximately 60 sites aiming
to enroll a total number of 200 subjects to ensure that at least 100 subjects will have 12
months exposure to PN400 (VIMOVO).
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec
Terminated
POZEN
Phase 3
2007-09-01
This randomized, double-blind, parallel-group, controlled, multi-center clinical trial of 6
months duration is designed to assess the efficacy, tolerability and safety of PN400 versus
diclofenac/misoprostol in subjects at high risk for developing NSAID-associated gastric
ulcers. Approximately 100 sites will participate to enroll a total of 200 subjects (100 per
arm).
At least 20% of the subjects enrolled will be age 65 years and older.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
